Promore Pharma

📍 Solna, Sweden🗓 Founded 2016👥 7 employees💰 Last funded May 2019
Biotechnology Research🌐 promorepharma.com
Website LinkedIn
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO"​).
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
2
Frequently asked questions
Who invested in Promore Pharma?
Promore Pharma has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Promore Pharma last raise funding?
The most recent investment in Promore Pharma recorded on gritt.io was in May 2019.
When was Promore Pharma founded?
Promore Pharma was founded in 2016.
What industry is Promore Pharma in?
Promore Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Promore Pharma based?
Promore Pharma is headquartered in Solna, Sweden.